T1 Biomarker 2025 2033 avelumab
T2 Level 675 690 death ligand 1 
T3 Organism 650 658 patients
T4 Biomarker 1798 1806 axitinib
T5 Gene 721 740 secondary end point
T6 Condition 1005 1026 PD-L1–positive tumors
T7 Organism 251 274 avelumab plus axitinib 
T8 Biomarker 1784 1792 avelumab
T9 Biomarker 924 932 axitinib
T10 Organism 938 946 patients
T11 Condition 1455 1476 PD-L1–positive tumors
T12 Biomarker 1521 1529 avelumab
T13 Organism 1924 1932 patients
T15 Biomarker 489 498 sunitinib
T16 Biomarker 2112 2122 first-line
T17 Biomarker 1559 1568 sunitinib
T18 Biomarker 1535 1543 axitinib
T19 Biomarker 1969 1985 Progression-free
T20 Organism 1441 1449 patients
T21 Organism 2074 2082 patients
T22 Biomarker 1108 1116 axitinib
T23 Biomarker 2039 2047 axitinib
T24 Organism 1829 1837 patients
T25 Intervention 507 513 orally
T26 Organism 1521 1544 avelumab plus axitinib 
T27 Organism 1768 1776 patients
T28 Organism 910 933 avelumab plus axitinib 
T29 Biomarker 265 273 axitinib
T30 Organism 1666 1674 patients
T31 Biomarker 283 309 standard-of-care sunitinib
T32 Condition 126 146 renal-cell carcinoma
T33 Condition 2146 2166 renal-cell carcinoma
T34 Biomarker 1845 1854 sunitinib
T35 Organism 876 884 patients
T36 Organism 966 974 patients
T37 Condition 221 241 renal-cell carcinoma
T38 Biomarker 451 459 axitinib
T39 Organism 2025 2048 avelumab plus axitinib 
T40 Organism 198 206 patients
T41 Organism 103 111 patients
T42 Biomarker 910 918 avelumab
T43 Biomarker 373 381 avelumab
T44 Biomarker 59 67 axitinib
T45 Organism 45 68 avelumab plus axitinib 
T46 Organism 338 346 patients
T47 Biomarker 1094 1102 avelumab
T48 Biomarker 2058 2067 sunitinib
T49 Intervention 467 473 orally
T50 Biomarker 951 960 sunitinib
T51 Biomarker 251 259 avelumab
T52 Organism_substance 417 431  intravenously
T53 Organism 1682 1690 patients
T54 Organism 991 999 patients
T55 Biomarker 45 53 avelumab
T56 Biomarker 1151 1160 sunitinib
